A Single-dose Zoledronic Acid Infusion Prevents Antiretroviral Therapy–induced Bone Loss in Treatment-naive HIV-infected Patients: A Phase IIb Trial | Zendy

Ighovwerha Ofotokun | Zendy; Kehmia Titanji | Zendy; Cecile D. Lahiri | Zendy; Aswani Vunnava | Zendy; Antonina Foster | Zendy; Sara E. Sanford | Zendy; Anandi N. Sheth | Zendy; Jeffrey L. Lennox | Zendy; Andrea Knežević | Zendy; Laura Ward | Zendy; Kirk A. Easley | Zendy; Pamela M. Powers | Zendy; M. Neale Weitzmann | Zendy

Open Access

A Single-dose Zoledronic Acid Infusion Prevents Antiretroviral Therapy–induced Bone Loss in Treatment-naive HIV-infected Patients: A Phase IIb Trial

Author(s) -

Ighovwerha Ofotokun,

Kehmia Titanji,

Cecile D. Lahiri,

Aswani Vunnava,

Antonina Foster,

Sara E. Sanford,

Anandi N. Sheth,

Jeffrey L. Lennox,

Andrea Knežević,

Laura Ward,

Kirk A. Easley,

Pamela M. Powers,

M. Neale Weitzmann

Publication year - 2016

Publication title -

clinical infectious diseases

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciw331

Subject(s) - zoledronic acid , medicine , antiretroviral therapy , human immunodeficiency virus (hiv) , tenofovir , oncology , pharmacology , viral load , virology

Human immunodeficiency virus (HIV) infection and antiretroviral therapy (ART) are associated with bone loss leading to increased fracture rate among HIV-infected individuals. ART-induced bone loss is most intense within the first 48 weeks of therapy, providing a window for prophylaxis with long-acting antiresorptives.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research